Nicotine Polacrilex Gum (2 mg) — Competitive Intelligence Brief

Nicotine Polacrilex Gum (2 mg) (Nicotine Polacrilex Gum (2 mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy. Area: Smoking Cessation / Addiction Medicine.

marketed Nicotine replacement therapy Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule

Target snapshot

Nicotine Polacrilex Gum (2 mg) (Nicotine Polacrilex Gum (2 mg)) — University of Hawaii. Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine Polacrilex Gum (2 mg) TARGET	Nicotine Polacrilex Gum (2 mg)	University of Hawaii	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Usual brand cigar	Usual brand cigar	Ohio State University Comprehensive Cancer Center	marketed		nicotinic acetylcholine receptors
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicotine Patch + Nicotine Gum	Nicotine Patch + Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Galantamine (Reminyl)	Galantamine (Reminyl)	Janssen-Cilag Pty Ltd	marketed	Acetylcholinesterase inhibitor with nicotinic receptor modulation	Acetylcholinesterase; nicotinic acetylcholine receptors
bupropion + nicotine gum	bupropion + nicotine gum	University of Wisconsin, Madison	marketed	Combination smoking cessation therapy (antidepressant + nicotine replacement)	Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine)
Nicotine replacement	Nicotine replacement	Instituto Fernandes Figueira	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy class)

1. University of Wisconsin, Madison · 2 drugs in this class
2. Iowa City Veterans Affairs Medical Center · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. University of Hawaii · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Vermont · 1 drug in this class
9. Ottawa Heart Institute Research Corporation · 1 drug in this class